Please assess the completion status of the following clinical trial:

Trial Title: AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* de novo or secondary acute myeloid leukemia of the FAB subtypes M0-M2 and M4-M7~* de novo or secondary myelodysplastic syndrome FAB subtypes RAEB and RAEB-T~* written informed consent~Exclusion Criteria:~* severe comorbidities~* severe uncontrolled complications of the leukemia~* previous therapy of leukemia/MDS~* HIV-Infection~* known relevant allergy against study medication~* pregnancy~* missing written informed consent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).